Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "novel transcript, antisense to RIMBP2" is a long non-coding RNA (lncRNA) transcribed from the DNA strand opposite to that of the RIMS binding protein 2 (RIMBP2) gene. Antisense RNAs are commonly produced across mammalian genomes and often act to regulate expression of their sense (protein-coding) gene partners through mechanisms such as transcriptional interference, chromatin modifications, or RNA duplex formation that can regulate mRNA stability or processing[3][6]. The precise function of this particular transcript remains unknown, and it is not currently considered a druggable or classical therapeutic target. In general, antisense transcripts across human genes can shape gene expression and cellular physiology through epigenetic or post-transcriptional mechanisms, but the vast majority, including ENSG00000296703, have not been functionally characterized in detail[3][6].
Not applicable; no drugs reported to target this transcript
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on novel transcript, antisense to RIMBP2 (ENSG00000296703).